Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 1 5Phase 4 2Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 4Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 3865Neoplasms 2990Prostatic Neoplasms 1754Colorectal Neoplasms 1431Lung Neoplasms 1331Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 663Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Hepatocellular 632Carcinoma, Non-Small-Cell Lung 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 486Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 376Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Melanoma 323Multiple Myeloma 322Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 280

Interventions

pazopanib 2Sorafenib 2Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase NA × Interventional × Refractory Solid Tumors × Clear all
NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
2 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Withdrawn
Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡